Pulmonx Corp — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
Pulmonx reported Q2 2026 revenue of $22.8M (down 5% YoY from $23.9M); U.S. revenue fell 4% to $14.2M, international fell 6% to $8.6M due to China sales suspension pending registration renewal. Net loss improved 34% to $10.1M ($0.24/share) from $15.2M ($0.38/share); adjusted EBITDA loss fell 39% to $5.1M from $8.4M. Gross margin expanded to 78% from 72%; operating expenses cut 16% to $26.8M from $32.0M. Cash stood at $55.8M. FY2026 guidance: $90–92M revenue, ~76% gross margin, $109–111M opex.
Why this rating
Moderate: loss contraction and margin expansion are positive, but absolute revenue decline and China suspension offset gains. Event material to ~$50M cap company, not transformational.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.